Lineage Cell Therapeutics Receivables

Lineage Cell Therapeutics (LCTX) currently reports a receivables of $790K as of June 2026. That compares with $260K in the prior-year period — up 208.6% year over year. Use the charts on this page to explore Lineage Cell Therapeutics's receivables history and peer comparisons.

Lineage Cell Therapeutics's receivables increased from $260K to $790K — a 208.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lineage Cell Therapeutics reported $790K in receivables as of June 2026. That compares with $260K in the prior-year period — up 208.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $790K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lineage Cell Therapeutics, and consider following LCTX for alerts when major investors trade the stock.

Lineage Cell Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $790K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LCTX with unrelated industries.